galantamine has been researched along with scopolamine hydrobromide in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.25) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 12 (37.50) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baraka, A; Harik, S | 1 |
| Cozanitis, DA | 1 |
| Briley, M; Chopin, P | 1 |
| Georgiev, VP; Yonkov, DI | 1 |
| Bores, GM; Camacho, F; Davis, L; Huger, FP; Kosley, RW; Mutlib, AE; Petko, W; Rush, DK; Selk, DE; Vargas, HM; Wolf, V | 1 |
| Harmon, HJ; Legako, JA; White, BJ | 1 |
| Bermudez, I; Groot-Kormelink, PJ; Smulders, CJ; van Kleef, RG; Vijverberg, HP; Zwart, R | 1 |
| Carelli, V; Costa, N; De Vita, D; Liberatore, F; Marra, R; Rispoli, V; Rotiroti, D; Scipione, L | 1 |
| De Groote, L; Dekeyne, A; Di Cara, B; Gobert, A; Millan, MJ; Panayi, F; Sicard, D | 1 |
| de Bruin, N; Pouzet, B | 1 |
| Bouchard, K; Hohnadel, E; Terry, AV | 1 |
| Chen, W; Mizoguchi, H; Mouri, A; Nabeshima, T; Nitta, A; Noda, Y; Wang, D; Zhou, Y | 1 |
| Fedotova, YO; Losev, NA; Sapronov, NS | 1 |
| Espinosa-Raya, J; Espinoza-Fonseca, M; Picazo, O; Trujillo-Ferrara, J | 1 |
| Chuang, TT; Gil-Bea, FJ; Marcos, B; Ramirez, MJ | 1 |
| Hoeffle-Maas, A; Jordis, U; Koepke, AK; Ludwig, J; Maelicke, A; Maus, A; Samochocki, M | 1 |
| Federley, M; Fjällström, AK; Persson, P; Stenqvist, P; Wadenberg, ML | 1 |
| Lai, M; Liu, H; Liu, Y; Ma, B; Sun, A; Zhang, F; Zhou, W; Zhou, X; Zhu, H | 1 |
| Bertorelli, R; Busquet, P; Capurro, V; Cavalli, A; Piomelli, D; Reggiani, A | 1 |
| Choi, JH; Hwang, IK; Jung, HY; Kim, JH; Kim, W; Nam, SM; Won, MH; Yoo, DY; Yoon, YS | 1 |
| Amatya, C; Dalhoff, Z; DeSaer, CJ; Eggerichs, MR; Ramakrishnan, L | 1 |
| Callaerts-Vegh, Z; D'Hooge, R; De Maeyer, JH; Lo, AC; Schuurkes, JA; Vermaercke, B | 1 |
| Ahnaou, A; Drinkenburg, WH; Huysmans, H; Jacobs, T | 1 |
| Boulouard, M; Dauphin, F; Freret, T; Hamidouche, K; Lecouflet, P; Lelong-Boulouard, V | 1 |
| Ali, EHA; Arafa, NMS; Hassan, MK | 1 |
| Mishra, DN; Singh, SK | 1 |
| Correa-Basurto, J; Farfán-García, ED; Fragoso-Vázquez, MJ; García-Marín, ID; Gómez-López, M; Joseph, E; Miliar-García, Á; Rosales-Hernández, MC; Torres-Ramos, MA; Villalobos-Acosta, DMÁ | 1 |
| Gzielo, K; Krawczyk, M; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Alexandrova, A; Georgieva, A; Kalfin, R; Lazarova, M; Petkova-Kirova, P; Stefanova, M; Tancheva, L; Tsekova, D; Tsvetanova, E; Uzunova, D; Vezenkov, L | 1 |
| Brinza, I; El-Kashak, W; Eldahshan, OA; Hritcu, L; Raey, MAE | 1 |
1 review(s) available for galantamine and scopolamine hydrobromide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
31 other study(ies) available for galantamine and scopolamine hydrobromide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Reversal of central anticholinergic syndrome by galanthamine.
Topics: Blood-Brain Barrier; Delirium; Delusions; Galantamine; Hallucinations; Humans; Injections, Intravenous; Male; Scopolamine; Sleep; Syndrome; Wakefulness | 1977 |
Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).
Topics: Adult; Central Nervous System; Coma; Delayed-Action Preparations; Galantamine; Hallucinations; Humans; Male; Scopolamine; Suicide | 1977 |
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.
Topics: Amnesia; Animals; Avoidance Learning; Cognition; Dihydroergotoxine; Dose-Response Relationship, Drug; Galantamine; Ginkgo biloba; Male; Nicergoline; Piracetam; Plant Extracts; Rats; Rats, Inbred Strains; Scopolamine; Secologanin Tryptamine Alkaloids; Tacrine; Yohimbine | 1992 |
Cholinergic influence on memory facilitation induced by angiotensin II in rats.
Topics: Acetylcholine; Angiotensin II; Animals; Avoidance Learning; Galantamine; Male; Memory; Oxotremorine; Rats; Rats, Inbred Strains; Scopolamine; Synaptic Transmission | 1990 |
Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Body Temperature; Cholinesterase Inhibitors; Galantamine; Humans; Male; Mice; Rats; Rats, Sprague-Dawley; Rats, Wistar; Scopolamine | 1996 |
Extended lifetime of reagentless detector for multiple inhibitors of acetylcholinesterase.
Topics: Acetylcholinesterase; Binding, Competitive; Biosensing Techniques; Cholinesterase Inhibitors; Diazinon; Enzymes, Immobilized; Equipment Design; Equipment Failure Analysis; Equipment Reuse; Galantamine; Indicators and Reagents; Octoxynol; Physostigmine; Porphyrins; Quality Control; Reproducibility of Results; Scopolamine; Sensitivity and Specificity; Spectrum Analysis; Tetracaine | 2003 |
Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism.
Topics: Acetylcholine; Alkaloids; Animals; Atropine; Azocines; Binding, Competitive; Cholinergic Agents; Cholinesterase Inhibitors; Dichlorvos; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Membrane Potentials; Models, Biological; Nicotine; Oocytes; Phenylcarbamates; Physostigmine; Plasmids; Quinolizines; Receptors, Nicotinic; Rivastigmine; Scopolamine; Tacrine; Xenopus laevis | 2005 |
Choline pivaloyl ester strengthened the benefit effects of Tacrine and Galantamine on electroencephalographic and cognitive performances in nucleus basalis magnocellularis-lesioned and aged rats.
Topics: Animals; Behavior, Animal; Choline; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electroencephalography; Enzyme Inhibitors; Galantamine; Male; Rats; Rats, Wistar; Scopolamine; Tacrine | 2006 |
Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.
Topics: Acetylcholine; Animals; Behavior, Animal; Benzazepines; Cholinesterase Inhibitors; Dopamine Antagonists; Extracellular Space; Galantamine; Hippocampus; Male; Microdialysis; Muscarinic Antagonists; Parasympathetic Nervous System; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Muscarinic; Recognition, Psychology; Scopolamine; Social Behavior; Synaptic Transmission | 2007 |
Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.
Topics: Animals; Behavior, Animal; Galantamine; Male; Mice; Nootropic Agents; Scopolamine | 2006 |
Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dizocilpine Maleate; Donepezil; Dose-Response Relationship, Drug; Drug Interactions; Gait Disorders, Neurologic; Galantamine; Indans; Inhibition, Psychological; Male; Nootropic Agents; Piperidines; Rats; Reflex, Startle; Scopolamine | 2007 |
The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems.
Topics: Amyloid beta-Peptides; Animals; Cognition Disorders; Conditioning, Psychological; Cues; Dopamine; Extracellular Space; Fear; Galantamine; Hippocampus; Injections, Intraventricular; Male; Memory; Mice; Mice, Inbred ICR; Muscarinic Antagonists; Peptide Fragments; Receptors, Nicotinic; Recognition, Psychology; Scopolamine; Synaptic Transmission | 2007 |
Antiamnesic effect of combined treatment with galantamine and estradiol in middle-aged ovariectomized female rats.
Topics: Amnesia; Animals; Estradiol; Estrogens; Female; Galantamine; Memory; Muscarinic Antagonists; Ovariectomy; Ovary; Rats; Scopolamine; Time Factors | 2006 |
Effect of a M1 allosteric modulator on scopolamine-induced amnesia.
Topics: Amnesia; Animals; Binding Sites; Cholinergic Agents; Conditioning, Classical; Drug Design; Galantamine; Male; Memory; Models, Molecular; Muscarinic Antagonists; Rats; Rats, Wistar; Receptor, Muscarinic M1; Scopolamine | 2007 |
Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Dizocilpine Maleate; Drug Administration Schedule; Drug Therapy, Combination; Galantamine; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Receptors, Serotonin; Scopolamine; Serotonin Antagonists; Sulfonamides; Thiophenes; Yawning | 2008 |
Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Brain Chemistry; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ferrets; Galantamine; Gastrointestinal Diseases; Humans; Mice; Scopolamine; Synaptic Transmission; Treatment Outcome | 2010 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Extrapyramidal Tracts; Galantamine; Haloperidol; Male; Mecamylamine; Motor Activity; Nicotinic Antagonists; Rats; Rats, Wistar; Receptors, Muscarinic; Risperidone; Schizophrenia; Scopolamine | 2011 |
Galantamine attenuates the heroin seeking behaviors induced by cues after prolonged withdrawal in rats.
Topics: Animals; Behavior, Animal; Cholinergic Antagonists; Cholinesterase Inhibitors; Cues; Drug-Seeking Behavior; Extinction, Psychological; Galantamine; Heroin; Mecamylamine; Motor Activity; Narcotics; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Scopolamine; Self Administration; Substance Withdrawal Syndrome; Ventral Tegmental Area | 2012 |
Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.
Topics: Amnesia; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Galantamine; Male; Memantine; Mice; Mice, Inbred Strains; Recognition, Psychology; Scopolamine | 2012 |
Effects of luteolin on spatial memory, cell proliferation, and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia model.
Topics: Acetylcholinesterase; Amnesia; Animals; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Proliferation; Cholinesterase Inhibitors; Dentate Gyrus; Doublecortin Protein; Galantamine; Lipid Peroxidation; Luteolin; Male; Maze Learning; Memory Disorders; Neurogenesis; Neuroprotective Agents; Rats; Scopolamine | 2013 |
Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.
Topics: Animals; Cholinesterase Inhibitors; Conditioning, Classical; Disease Models, Animal; Dose-Response Relationship, Drug; Galantamine; Hyperkinesis; Locomotion; Memory; Muscarinic Antagonists; Planarians; Scopolamine; Stereotypic Movement Disorder; Time Factors | 2014 |
SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl/6 mice.
Topics: Animals; Anxiety; Avoidance Learning; Benzofurans; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Galantamine; Male; Maze Learning; Memory Disorders; Mice, Inbred C57BL; Nootropic Agents; Piperidines; Random Allocation; Receptors, Serotonin, 5-HT4; Scopolamine; Serotonin 5-HT4 Receptor Agonists | 2014 |
Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
Topics: Animals; Cerebral Cortex; Cognition; Donepezil; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Galantamine; Gamma Rhythm; Indans; Male; Memantine; Motor Activity; Muscarinic Antagonists; Neural Pathways; Nootropic Agents; Phenylcarbamates; Piperidines; Principal Component Analysis; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Signal Processing, Computer-Assisted; Tacrine; Theta Rhythm | 2014 |
Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse.
Topics: Allosteric Regulation; Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Galantamine; Male; Memory Disorders; Mice; Nicotinic Antagonists; Piperidines; Receptors, Nicotinic; Receptors, Serotonin, 5-HT4; Scopolamine; Serotonin 5-HT4 Receptor Agonists | 2017 |
Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action.
Topics: Acetylcholinesterase; Animals; Canagliflozin; Galantamine; Hippocampus; Hypoglycemic Agents; Male; Maze Learning; Memory; Memory Disorders; Rats; Rats, Wistar; Scopolamine | 2017 |
Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice.
Topics: Acetylcholinesterase; Adhesiveness; Administration, Intranasal; Administration, Oral; Alzheimer Disease; Animals; Behavior, Animal; Biological Availability; Blood-Brain Barrier; Chitosan; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Galantamine; Humans; Male; Maze Learning; Mice; Nanoparticles; Nasal Mucosa; Nootropic Agents; Piracetam; Scopolamine; Treatment Outcome | 2019 |
Neuroprotective Effects of Apocynin and Galantamine During the Chronic Administration of Scopolamine in an Alzheimer's Disease Model.
Topics: Acetophenones; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Galantamine; Hippocampus; Male; NADPH Oxidase 2; Neuroprotective Agents; NF-kappa B; Oxidative Stress; Rats; Rats, Wistar; Scopolamine | 2020 |
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Synergism; Excitatory Amino Acid Antagonists; Galantamine; Isoxazoles; Memantine; Nootropic Agents; Phenylurea Compounds; Rats; Recognition, Psychology; Scopolamine | 2020 |
Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice.
Topics: Alzheimer Disease; Animals; Antioxidants; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Male; Memory, Long-Term; Memory, Short-Term; Mice; Scopolamine | 2021 |
Sweroside Ameliorated Memory Deficits in Scopolamine-Induced Zebrafish (
Topics: Acetylcholinesterase; Animals; Anti-Bacterial Agents; Antifungal Agents; Antioxidants; Brain; Cholinergic Agents; Galantamine; Glucose; Hypnotics and Sedatives; Imipramine; Iridoid Glucosides; Maze Learning; Memory Disorders; Oxidative Stress; Scopolamine; Sugars; Zebrafish | 2022 |